Summary

• The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
• Please refer to the local labeling for relevant information regarding geriatric use of ICOTYDE.

COMPANY CORE DATA SHEET

Special Populations

Elderly (65 years of age and older)

• Of the 2367 subjects exposed to ICOTYDE in clinical trials for psoriasis, 240 (10%) were 65 years of age and older, and 36 (1.5%) were 75 years of age or older.¹ 
• No overall differences in safety and effectiveness of ICOTYDE have been observed between subjects 65 years and older and younger adult subjects.¹ 

Pharmacokinetic Properties

Elderly (65 years of age and older)

• No apparent differences in clearance were observed in subjects ≥65 years of age compared to subjects <65 years of age, suggesting no dose adjustment is needed for elderly subjects.¹ 

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) was conducted on 8 March 2026.